1404P A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results

This article has no abstract
Epistemonikos ID: 06d2041c08f5071eecfa732c9395ab06d770067f
First added on: Feb 15, 2025